Cardiome Pharma Corp. (USA) (NASDAQ:CRME)

CAPS Rating: 3 out of 5

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

Recs

0
Player Avatar cavrad (< 20) Submitted: 2/19/2011 2:20:42 PM : Outperform Start Price: $5.89 CRME Score: -94.14

mfi

Featured Broker Partners


Advertisement